Clinical trials: Transplacental Maternal Engraftment
Severe Combined Immunodeficiency, Transplacental Maternal Engraftment
Sirolimus Prophylaxis for aGVHD in TME SCID
Study Design: SCID infants receiving an unconditioned haploidentical transplant will be started on Sirolimus (0.05 mg/kg/day) day -5 for Acute Graft-Versus-Host Disease (aGVHD) prophylaxis.
- Conditions
- Severe Combined Immunodeficiency, Transplacental Maternal Engraftment, Stem Cell Transplant
- Trial name
- NCT02177760
- Testing
- Sirolimus
- Where
- United States
- Sponsor
- University of California, San Francisco